Sarepta, Elevidys, and the Future of AAV Gene Therapy

Subscribe to Biotech Blueprint HERE and to Biotech Capital Compass HERE.In this episode of the Biotech Blueprint podcast, I teamed up with the Biotech Capital Compass to break down Sarepta Therapeutics’ recent safety crisis, and what the FDA’s partial green light means for Elevidys, investor confidence, and the broader AAV field. We dig into the science, regulatory dynamics, and what might come next.